ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 51 of 124 for:    vitiligo

Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03371758
Recruitment Status : Recruiting
First Posted : December 13, 2017
Last Update Posted : January 23, 2018
Sponsor:
Information provided by (Responsible Party):
Maha Fathy Elmasry, Cairo University

Brief Summary:
The exact mechanism of impairment of autophagy in vitiligo has not yet been determined.

Condition or disease Intervention/treatment Phase
Autophagy Other: skin biopsy Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo and Healthy Control; Comparative Study
Actual Study Start Date : January 2017
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitiligo

Arm Intervention/treatment
Experimental: vitiligo patients Other: skin biopsy
Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.

Experimental: healthy controls Other: skin biopsy
Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.




Primary Outcome Measures :
  1. Expression of LC3-I, LC3-II & Beclin 1 in vitiligo patients [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • • Patients with non-segmental vitiligo whether active or stable.

    • Age above 12 years.
    • Both sexes.

Exclusion Criteria:

  • • Patients should not use any topical or systemic treatment at least 6 weeks before inclusion into the study.

    • Patients having other autoimmune disease, heart disease, liver disease, kidney disease, neurological disorder, cancer, active infection or any chronic disease.
    • Pregnancy or breast feeding for female patients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03371758


Locations
Egypt
Maha Fathy Elmasry Recruiting
Cairo, Egypt
Contact: Maha Fathy Elmasry, MD       mahafathy1214@gmail.com   
Sponsors and Collaborators
Cairo University

Responsible Party: Maha Fathy Elmasry, Principal investigator, Cairo University
ClinicalTrials.gov Identifier: NCT03371758     History of Changes
Other Study ID Numbers: Dermatology
First Posted: December 13, 2017    Key Record Dates
Last Update Posted: January 23, 2018
Last Verified: January 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases